Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Filings indexed 416 across all filing types
Latest filing 2026-03-30 Major Shareholding Noti…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 93% confidence The document is a TR-1 standard form notification under EU DTR for a major shareholding crossing a threshold (Oxford BioDynamics PLC disclosure of Trafalgar Capital Management’s voting rights change). This matches a Major Shareholding Notification (MRQ).
2026-03-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Oxford BioDynamics PLC. This form is specifically used to report changes in significant share ownership (major holdings) as required by regulatory transparency rules. It details the acquisition or disposal of voting rights by Trafalgar Capital Management (HK) Limited. This fits the definition of a Major Shareholding Notification (MRQ).
2026-03-20 English
OBD to present at PMWC 2026
Regulatory Filings Classification · 95% confidence The document is a press release issued via the RNS (Regulatory News Service) platform announcing that Oxford BioDynamics PLC will be presenting at the Precision Medicine World Conference (PMWC) 2026. It does not contain financial results, governance changes, or other specific regulatory disclosures, but rather serves as a corporate announcement regarding company activities and public relations. As it does not fit into the specific categories like 10-K, ER, or IP (which would be a slide deck), it falls under the fallback category for general regulatory announcements.
2026-03-03 English
Change of Nominated Adviser
Regulatory Filings Classification · 100% confidence The document is an official announcement from Oxford BioDynamics PLC regarding the appointment of a new Nominated Adviser and Broker. This type of corporate announcement, which does not fit into specific categories like financial reports or shareholder meetings, is classified as a general regulatory announcement. Given the RNS (Regulatory News Service) header and the nature of the content (corporate administrative update), it falls under the RNS category.
2026-02-17 English
Group of companies' accounts made up to 2025-09-30
Regulatory Filings
2026-02-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Oxford BioDynamics PLC. It details a change in share ownership by Sankofa Strategic Equity Fund Ltd, specifically noting that the shareholder's voting rights have crossed a threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.